Cellectar Biosci receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc stock price live, this page displays NASDAQ CLRB stock exchange data. View the CLRB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Cellectar Biosciences Inc real time stock price chart below.
What Is the Cellectar Biosciences Inc Stock Price Today?
The Cellectar Biosciences Inc stock price today is 3.3447.
What Is the Stock Symbol for Cellectar Biosciences Inc?
The stock symbol for Cellectar Biosciences Inc is "CLRB."
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLRB quote. (ISIN: US15117F8804)
What Is the Cellectar Biosciences Inc Stock Price Today?
The Cellectar Biosciences Inc stock price today is 3.3447.
What Is the Stock Symbol for Cellectar Biosciences Inc?
The stock symbol for Cellectar Biosciences Inc is "CLRB."
What Stock Exchange Does Cellectar Biosciences Inc Trade On?
Cellectar Biosciences Inc is listed and trades on the NASDAQ stock exchange.
Is Cellectar Biosciences Inc a Good Stock to Buy?
Determining whether Cellectar Biosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CLRB quote. (ISIN: US15117F8804)
3.2800
+0.0500(+1.55%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2700
3.4400
52 wk Range
2.4500
20.5947
CLRB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.27003.4400
52 wk Range
2.450020.5947
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CLRB Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
33.3333
Upside
+916.26%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K Cellectar Biosciences Inc For: 4 March
- Investing.com
- Cellectar Biosci receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Cellectar Biosciences Inc For: 4 March
- Investing.com
- Form 13G Cellectar Biosciences For: 10 February
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company’s lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom’s macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin’s lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Cellectar Biosciences Inc Earnings Call Summary for Q4/2025
- Cellectar reduced net loss 51.1% YoY to $21.8M; R&D and SG&A expenses each fell ~55%, extending cash runway into Q3 2026.
- Cash position declined to $13.2M from $23.3M; stock rose 4.1% premarket despite trading 87% below 52-week high amid clinical progress.
- Company plans European Conditional Marketing Authorization for Iopofosine I-131 by Q3 2026, targeting 2027 commercialization.
- FDA submission expected after confirmatory Phase III trial initiation; management emphasizes operational efficiency to advance clinical pipeline.
- Key risks include regulatory approval delays, intense radiopharmaceutical competition, and financial constraints limiting future R&D investments.
Last Updated: 2026-03-04, 10:14 a/m
Read Full TranscriptCompare CLRB to Peers and Sector
Metrics to compare | CLRB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLRBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.7x | −3.8x | −0.5x | |
PEG Ratio | −0.01 | 0.26 | 0.00 | |
Price/Book | 1.8x | 6.5x | 2.6x | |
Price / LTM Sales | - | 8.3x | 3.2x | |
Upside (Analyst Target) | 333.4% | 71.6% | 53.2% | |
Fair Value Upside | Unlock | 9.9% | 7.6% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 33.3333
(+916.26% Upside)
Earnings
Latest Release
Mar 04, 2026
EPS / Forecast
-1.29 / -0.1416
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Cellectar Biosciences (CLRB) Stock Price Today?
The Cellectar Biosciences stock price today is 3.2800 USD.
What Stock Exchange Does Cellectar Biosciences Trade On?
Cellectar Biosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Cellectar Biosciences?
The stock symbol for Cellectar Biosciences is "CLRB."
What Is the Cellectar Biosciences Market Cap?
As of today, Cellectar Biosciences market cap is 14.3300M USD.
What Is Cellectar Biosciences's Earnings Per Share (TTM)?
The Cellectar Biosciences EPS (TTM) is -8.3500.
From a Technical Analysis Perspective, Is CLRB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Cellectar Biosciences Stock Split?
Cellectar Biosciences has split 6 times.
How Many Employees Does Cellectar Biosciences Have?
Cellectar Biosciences has 11 employees.
What is the current trading status of Cellectar Biosciences (CLRB)?
As of Mar 13, 2026, Cellectar Biosciences (CLRB) is trading at a price of 3.2800 USD, with a previous close of 3.2300 USD. The stock has fluctuated within a day range of 3.2700 USD to 3.4400 USD, while its 52-week range spans from 2.4500 USD to 20.5947 USD.
What Is Cellectar Biosciences (CLRB) Price Target According to Analysts?
The average 12-month price target for Cellectar Biosciences is 33.3333 USD, with a high estimate of 76 USD and a low estimate of 10 USD. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +916.26% Upside potential.
What Is the CLRB Premarket Price?
CLRB's last pre-market stock price is 3.2900 USD. The pre-market share volume is 277.0000, and the stock has decreased by 0.0600, or 1.8600%.
What Is the CLRB After Hours Price?
CLRB's last after hours stock price is 3.2600 USD, the stock has decreased by 0.0300, or 0.9300%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.